Literature DB >> 29369467

Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study.

M Harris1, O Bonnington1, G Harrison2, M Hickman3, W Irving2.   

Abstract

The United Kingdom has committed to eliminating viral hepatitis as a public health threat. Innovative interventions for marginalized populations are required to realize this goal. In 2016, the HepCATT study team implemented a complex hepatitis C (HCV) intervention in three English drug treatment services, with five controls. We report qualitative study findings from two intervention sites to explore intervention success and transferability potential. The intervention comprised multiple components, including a nurse facilitator, peer support and education initiatives. Qualitative data were generated at baseline (2014) and post-intervention (2016) at two sites through in-depth interviews, focus groups and observations. The 96 participants comprised drug service and intervention providers and clients with an injecting history. Data were triangulated and thematically analysed. Client engagement with a HCV treatment service rose from 16 at baseline to 147 in 2016. There was no comparable increase at the five control sites. Baseline testing and treatment barriers included the following: limited HCV knowledge; fear of diagnosis and treatment; precarious living circumstances and service-specific obstacles. Treatment engagement was aided by intervention timeliness; improved communication structures; personalized care; streamlined testing and treatment pathways; peer support. Multiple interrelated components influenced the increased levels of treatment engagement documented in HepCATT. The nurse facilitator, involved in implementation and innovation, was key to intervention success. Baseline barriers correspond with international literature-indicating transferability potential. Control data indicate that biomedical innovation alone is not sufficient to increase engagement among the most marginalized. Sustainable resourcing of community services is crucial to effect change.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis C; intervention; people who inject drugs; qualitative; treatment

Mesh:

Substances:

Year:  2018        PMID: 29369467     DOI: 10.1111/jvh.12869

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

Review 1.  Hepatitis C models of care: approaches to elimination.

Authors:  Mia J Biondi; Jordan J Feld
Journal:  Can Liver J       Date:  2020-06-04

2.  Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis.

Authors:  Aaron G Lim; Josephine G Walker; Nyashadzaishe Mafirakureva; Gul Ghuttai Khalid; Huma Qureshi; Hassan Mahmood; Adam Trickey; Hannah Fraser; Khawar Aslam; Gregoire Falq; Camille Fortas; Hassaan Zahid; Ammara Naveed; Rosa Auat; Quaid Saeed; Charlotte F Davies; Christinah Mukandavire; Nancy Glass; David Maman; Natasha K Martin; Matthew Hickman; Margaret T May; Saeed Hamid; Anne Loarec; Francisco Averhoff; Peter Vickerman
Journal:  Lancet Glob Health       Date:  2020-03       Impact factor: 26.763

3.  Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.

Authors:  Alain H Litwin; Martine Drolet; Chizoba Nwankwo; Martha Torrens; Andrej Kastelic; Stephan Walcher; Lorenzo Somaini; Emily Mulvihill; Jochen Ertl; Jason Grebely
Journal:  J Viral Hepat       Date:  2019-06-11       Impact factor: 3.728

4.  Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.

Authors:  Jason Grebely; Phillip Read; Evan B Cunningham; Martin Weltman; Gail V Matthews; Adrian Dunlop; Mark Montebello; Marianne Martinello; Rosie Gilliver; Philippa Marks; Tanya L Applegate; Gregory J Dore
Journal:  Health Sci Rep       Date:  2020-03-15

5.  A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.

Authors:  Jacqueline E Sherbuk; Alexa Tabackman; Kathleen A McManus; Terry Kemp Knick; Julie Schexnayder; Tabor E Flickinger; Rebecca Dillingham
Journal:  Harm Reduct J       Date:  2020-09-18

6.  Exploring and understanding HCV patient journeys- HEPCARE Europe project.

Authors:  Shannon Glaspy; Gordana Avramovic; Tina McHugh; Cristiana Oprea; Julian Surey; Irina Ianache; Juan Macías; Alistair Story; Walter Cullen; John S Lambert
Journal:  BMC Infect Dis       Date:  2021-03-05       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.